Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/42990
Title: | An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients | Authors: | Debing, Yannick VANRUSSELT, Hannah Degrauwe, Lars de Oliveira, Daniel Apolonio Silva Kariuki, Christopher Kinyanjui Ebwanga, Ebanja Joseph Bashir, Shahbaz Merckx, Wouter Thatikonda, Santhosh Kumar Rajwanshi, Vivek Gohil, Vikrant Hong, Jin Kum, Dieudonne Buh Sanchez, Abel Acosta Chanda, Sushmita Blatt, Lawrence M. Jekle, Andreas Symons, Julian A. Smith, David B. Raboisson, Pierre Lin, Tse-, I Beigelman, Leonid Paeshuyse, Jan |
Issue Date: | 2024 | Publisher: | ELSEVIER | Source: | ANTIVIRAL RESEARCH, 224 (Art N° 105835) | Abstract: | Nucleic acid polymers (NAPs) are an attractive treatment modality for chronic hepatitis B (CHB), with REP2139 and REP2165 having shown efficacy in CHB patients. A subset of patients achieve functional cure, whereas the others exhibit a moderate response or are non-responders. NAP efficacy has been difficult to recapitulate in animal models, with the duck hepatitis B virus (DHBV) model showing some promise but remaining underexplored for NAP efficacy testing. Here we report on an optimized in vivo DHBV duck model and explore several characteristics of NAP treatment. REP2139 was efficacious in reducing DHBV DNA and DHBsAg levels in approximately half of the treated ducks, whether administered intraperitoneally or subcutaneously. Intrahepatic or serum NAP concentrations did not correlate with efficacy, nor did the appearance of anti-DHBsAg antibodies. Furthermore, NAP efficacy was only observed in experimentally infected ducks, not in endogenously infected ducks (vertical transmission). REP2139 add-on to entecavir treatment induced a deeper and more sustained virological response compared to entecavir monotherapy. Destabilized REP2165 showed a different activity profile with a more homogenous antiviral response followed by a faster rebound. In conclusion, subcutaneous administration of NAPs in the DHBV duck model provides a useful tool for in vivo evaluation of NAPs. It recapitulates many aspects of this class of compound's efficacy in CHB patients, most notably the clear division between responders and non-responders. | Notes: | Debing, Y (corresponding author), Aligos Belgium BV, Leuven, Belgium.; Paeshuyse, J (corresponding author), Katholieke Univ Leuven, Dept Biosyst, Lab Host Pathogen Interact, Leuven, Belgium. ydebing@aligos.com; jan.paeshuyse@kuleuven.be |
Keywords: | Duck hepatitis B virus;Chronic hepatitis B;Antiviral therapy;Nucleic acid polymer;Ducks | Document URI: | http://hdl.handle.net/1942/42990 | ISSN: | 0166-3542 | e-ISSN: | 1872-9096 | DOI: | 10.1016/j.antiviral.2024.105835 | ISI #: | 001209075500001 | Rights: | 2024 Elsevier B.V. All rights reserved. | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients.pdf Restricted Access | Published version | 8.33 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.